Periodic Reporting for period 1 - ExcellPharmTech (Center of Excellence in Advanced Pharmaceutical Technologies)
Berichtszeitraum: 2023-03-01 bis 2024-05-31
Masaryk University (MU) is the second-largest university in the Czech Republic located in Brno. Thanks to the ESIF funding, MU was able to acquire top research infrastructure attracting talented researchers who gradually built the position of the MU as the top regional
hub for education, research, and innovation. To further exploit this potential, the management structures and processes of the university must thoroughly implement the European Research Area (ERA) Priorities. As an outstanding researcher/innovator can have a decisive
and positive impact on the culture and performance of any institution, MU will recruit a world-class research manager as an ERA Chair for its newly-established Faculty of Pharmacy.
The Faculty of Pharmacy (MUNI Pharm) is, besides others, focused on the development of advanced drug formulations and molecular biology techniques. The ERA Chair will intensify the research and development of advanced drug formulation and nanotechnologies to open new opportunities to intensify MUNI Pharm research capacities in the pharmacy field and develop strategic partnerships with the application sphere and public sector for faster translation of the advanced drugs into clinics.
The recruitment of leading scientist will enforce the connection of the MUNI Pharm to the research structures of MU, and the ERA Chair will make a bridge in the formation of a unique education and research facility at one place titled MUNI BioPharma Hub, supported from National Recovery Plan (part of RRF – Recovery and Resilience Facility, NextGeneration EU). To solve the targeted delivery and transportation of nucleic acids into the target cell environment, the MUNI Pharm will establish an interdisciplinary center of excellence (Pharma Center of Excellence in Advanced Technology) with ERA Chair as its leader. Creating an international ERA Chair team will ensure a successful establishment of the center, combining excellent research, high level education, and top innovations.
hub for education, research, and innovation. To further exploit this potential, the management structures and processes of the university must thoroughly implement the European Research Area (ERA) Priorities. As an outstanding researcher/innovator can have a decisive
and positive impact on the culture and performance of any institution, MU will recruit a world-class research manager as an ERA Chair for its newly-established Faculty of Pharmacy.
The Faculty of Pharmacy (MUNI Pharm) is, besides others, focused on the development of advanced drug formulations and molecular biology techniques. The ERA Chair will intensify the research and development of advanced drug formulation and nanotechnologies to open new opportunities to intensify MUNI Pharm research capacities in the pharmacy field and develop strategic partnerships with the application sphere and public sector for faster translation of the advanced drugs into clinics.
The recruitment of leading scientist will enforce the connection of the MUNI Pharm to the research structures of MU, and the ERA Chair will make a bridge in the formation of a unique education and research facility at one place titled MUNI BioPharma Hub, supported from National Recovery Plan (part of RRF – Recovery and Resilience Facility, NextGeneration EU). To solve the targeted delivery and transportation of nucleic acids into the target cell environment, the MUNI Pharm will establish an interdisciplinary center of excellence (Pharma Center of Excellence in Advanced Technology) with ERA Chair as its leader. Creating an international ERA Chair team will ensure a successful establishment of the center, combining excellent research, high level education, and top innovations.
Unfortunately, technical and scientific aspects of the project can not be listed, since the project realization came to an end before any of the main achievements could have been reached. Termination of the project is a consequence of the ERA Chair difficulties with relocation caused by personal obstacles and the impossibility of hiring a new person for this position according to the specific conditions of the call and the topic of the project.
As a consequence of project termination, results beyond the state of arts of the project can not be listed since the project realization came to an end before any research or impact of the project activities may take place.